Products from BPS Bioscience require a minimum order value above 400€
Applications: 1. Study the mechanism of viral transduction
2. Screening for neutralizing antibodies that inhibit the interaction between ACE2 and the Spike protein of SARS-CoV-2 variants.
3. Identify variant-specific antibodies recognizing the different Spike mutations.
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Numerous SARS-CoV-2 variants have been identified so far. These variants contain a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than the original strain.BPS Bioscience has launched a series of Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter). The Spike (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike Variant (see below for mutation details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus Pack (Luciferase Reporter) contains a collection of 12 Spike variants (SARS-CoV-2) Pseudotyped lentivirus (Luc reporter). It is a great tool to screen for variant-specific antibodies or to test the binding or efficacy of drug candidates against the different Spike variants. The Spike (SARS-CoV-2) pseudotyped lentiviruses can be used to measure the activity of neutralizing antibody against SARS-CoV-2 infection in a Biosafety Level 2 facility.
Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS.Thaw Medium 1 (BPS Bioscience, #60187): MEM medium (Hyclone, #SH30024.01) supplemented with 10% FBS, 1% non-essential amino acids (Hyclone, #SH30238.01), 1 mM Na pyruvate, 1% Penicillin/Streptomycin (Hyclone, #SV30010.01).
Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C.
Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle.Biosafety: None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Biosafety Level: BSL-2
English
Deutsch
